Overexpression of Cyclooxygenase-2 in Malignant Peripheral Nerve Sheath Tumor and Selective Cyclooxygenase-2 Inhibitor-Induced Apoptosis by Activating Caspases in Human Malignant Peripheral Nerve Sheath Tumor Cells
Background Cyclooxygenase-2 (COX-2) is a key enzyme in the conversion of arachidonic acid to prostanoids, and its activation is associated with carcinogenesis as well as inflammation. The antitumor effect of selective COX-2 inhibitors has been noted in various malignancies. Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive soft tissue sarcoma for which effective treatments have not yet been established. The purpose of this study was to investigate a potential therapeutic role of COX-2 in MPNST. Methods We evaluated the expression of COX-2 in 44 cases of high-grade MPNST using immunohistochemical staining and compared the staining results with the characteristics and outcome of the patients. We also investigated the antitumor effect of etodolac, a selective COX-2 inhibitor, on MPNST cells in vitro using the MPNST cell line, FMS-1. Results Overexpression of COX-2 (≥50% positive cells) was observed in 29 cases (65.9%), was significantly associated with a poor overall survival (P = 0.0495), and was considered an independent risk factor for a poor outcome by the results of both univariate and multivariate analysis. Etodolac induced apoptosis of FMS-1 cells through the activation of caspase-8, -9, and -3. Moreover, several caspase inhibitors significantly inhibited etodolac-induced apoptosis. Conclusions Selective COX-2 inhibitors including etodolac had an antitumor effect on MPNST cells, and their use holds promise as a novel therapeutic strategy for patients with MPNST to improve their prognoses.
References
[1]
Nielsen GP, Antonescu CR, Lothe RA (2013) Malignant peripheral nerve sheath tumour. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone, 4th ed. Lyon: IARC. 187–189.
[2]
Weiss SW, Goldblum JR (2007) Malignant tumors of the peripheral nerves. In: Weiss SW, Goldblum JR, editors. Enzinger and Weiss’s soft tissue tumors, 5th ed. Philadelphia: Mosby/Elsevier. 903–917.
[3]
Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN (2008) Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 97: 340–349. doi: 10.1002/jso.20971
[4]
Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120. doi: 10.1146/annurev.pharmtox.38.1.97
[5]
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, et al. (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073.
[6]
Endo M, Matsumura T, Yamaguchi T, Yamaguchi U, Morimoto Y, et al. (2006) Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol 37: 471–476.
[7]
Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, et al. (2008) COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol 30: 507–512. doi: 10.1097/mph.0b013e31816e238c
[8]
Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N (2009) Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 467: 2932–2938. doi: 10.1007/s11999-009-0814-x
[9]
Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN (2010) Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med 150: 237–242. doi: 10.1007/s10517-010-1114-x
[10]
Lee CH, Roh JW, Choi JS, Kang S, Park IA, et al. (2011) Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 21: 668–672. doi: 10.1097/igc.0b013e3182150d56
[11]
Wang D, DuBois RN (2006) Prostaglandins and cancer. Gut 55: 115–122. doi: 10.1136/gut.2004.047100
[12]
Moalic S, Liagre B, Le Bail JC, Beneytout JL (2001) Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 18: 533–540. doi: 10.3892/ijo.18.3.533
[13]
Moalic-Juge S, Liagre B, Duval R, Corbiere C, Bianchi A, et al. (2002) The anti-apoptotic property of NS-398 at high dose can be mediated in part through NF-kappaB activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells. Int J Oncol 20: 1255–1262. doi: 10.3892/ijo.20.6.1255
[14]
Yamashita H, Osaki M, Honjo S, Yoshida H, Teshima R, et al. (2003) A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 23: 4671–4676.
[15]
Naruse T, Nishida Y, Hosono K, Ishiguro N (2006) Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584–592. doi: 10.1093/carcin/bgi240
[16]
Hakozaki M, Hojo H, Kikuchi S, Abe M (2007) Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1). Oncol Rep 17: 169–173. doi: 10.3892/or.17.1.169
[17]
Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, et al. (2007) Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol 15: 70–76. doi: 10.1097/01.pai.0000213131.63417.fa
[18]
Liu B, Shi ZL, Feng J, Tao HM (2008) Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 32: 494–501. doi: 10.1016/j.cellbi.2007.10.008
[19]
Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, et al. (2010) COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer 46: 616–624. doi: 10.1016/j.ejca.2009.11.002
[20]
Gendy AS, Lipskar A, Glick RD, Steinberg BM, Edelman M, et al. (2011) Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. J Pediatr Surg 46: 108–114. doi: 10.1016/j.jpedsurg.2010.09.074
[21]
Reed S, Li H, Li C, Lin J (2011) Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. Biochem Biophys Res Commun 407: 450–455. doi: 10.1016/j.bbrc.2011.03.014
[22]
Hakozaki M, Hojo H, Sato M, Tajino T, Yamada H, et al. (2006) Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2. Anticancer Res 26: 3393–3401.
[23]
Hakozaki M, Hojo H, Sato M, Tajino T, Yamada H, et al. (2009) Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. Virchows Arch 455: 517–526. doi: 10.1007/s00428-009-0848-1
[24]
Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP (2003) Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 25: 282–285. doi: 10.1097/00043426-200304000-00003
[25]
Yamashita H, Osaki M, Ardyanto TD, Osaki M, Yoshida H, et al. (2004) Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 14: 565–570. doi: 10.3892/ijmm.14.4.565
[26]
Herceg ME, Tsiatis AC, Halpern JL, Holt GE, Schwartz HS, et al. (2009) Cyclooxygenase 2 expression in soft tissue leiomyosarcoma. Anticancer Res 29: 2913–2917.
[27]
Nakagawa SA, Lopes A, Lopes de Carvalho A, Rossi BM, Werneck da Cunha I, et al. (2010) Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92: 1738–1746. doi: 10.2106/jbjs.h.00717
[28]
Carmody Soni EE, Miller BJ, Scarborough MT, Reith J, Parker Gibbs C (2011) Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma. Oncol Rep 26: 1513–1517. doi: 10.3892/or.2011.1431
[29]
Sutton KM, Wright M, Fondren G, Towle CA, Mankin HJ (2004) Cyclooxygenase-2 expression in chondrosarcoma. Oncology 66: 275–280. doi: 10.1159/000078327
[30]
Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, et al. (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107: 1065–1074. doi: 10.1002/cncr.22098
[31]
Okada K, Hasegawa T, Tajino T, Hotta T, Yanagisawa M, et al. (2007) Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol 14: 597–604. doi: 10.1245/s10434-006-9053-5
[32]
Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL (1998) Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42: 351–360. doi: 10.1016/s0360-3016(98)00223-5
[33]
Baehring JM, Betensky RA, Batchelor TT (2003) Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 61: 696–698. doi: 10.1212/01.wnl.0000078813.05925.2c
[34]
Salas S, Bui B, Stoeckle E, Terrier P, Ranchere-Vince D, et al. (2009) Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database. Ann Oncol 20: 1127–1135. doi: 10.1093/annonc/mdn757
[35]
Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, et al. (2011) Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res 17: 3771–3782. doi: 10.1158/1078-0432.ccr-10-2393
[36]
Mazhar D, Ang R, Waxman J (2006) COX inhibitors and breast cancer. Br J Cancer 94: 346–350.
[37]
Bernard MP, Bancos S, Sime PJ, Phipps RP (2008) Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 14: 2051–2060. doi: 10.2174/138161208785294654
[38]
Ola MS, Nawaz M, Ahsan H (2011) Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41–58. doi: 10.1007/s11010-010-0709-x
[39]
Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245–4249.
[40]
Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F (2002) Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903–4908.
Li M, Wu X, Xu XC (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010–1016. doi: 10.1002/ijc.1322
[43]
Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, et al. (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397–11403. doi: 10.1074/jbc.275.15.11397
Jendrossek V (2013) Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett 332: 313–324. doi: 10.1016/j.canlet.2011.01.012
[46]
Kasper B, Ho AD, Egerer G (2005) A new therapeutic approach in patients with advanced sarcoma. Int J Clin Oncol 10: 438–440. doi: 10.1007/s10147-005-0514-9
[47]
McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098. doi: 10.1371/journal.pmed.1001098
[48]
Brater DC, Lasseter KC (1989) Profile of etodolac: pharmacokinetic evaluation in special populations. Clin Rheumatol 8 Suppl 125–35. doi: 10.1007/bf02214107
[49]
Fletcher CD, Dal Cin P, de Wever I, Mandahl N, Mertens F, et al. (1999) Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. Am J Pathol 154: 1841–1847. doi: 10.1016/s0002-9440(10)65441-7
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45: 575–578. doi: 10.1001/archneur.1991.00530240100030
[52]
Enneking WF, Maale GE (1981) The effect of inadvertent tumor contamination of wounds during the surgical resection of musculoskeletal neoplasms. Cancer 62: 1251–1256. doi: 10.1002/1097-0142(19881001)62:7<1251::aid-cncr2820620702>3.0.co;2-4
[53]
Bajorath J (1999) Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface. J Comput Aided Mol Des 13: 409–418.
